# EDGAR Filing Document

**Accession Number:** 0001730463
**File Stem:** 0001730463-23-000007
**Filing Date:** 2023-1
**Character Count:** 7587
**Document Hash:** 231962d4057826fa7d89366f240a1691
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001730463-23-000007.hdr.sgml**: 20230123

**ACCESSION NUMBER**: 0001730463-23-000007

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 3

**CONFORMED PERIOD OF REPORT**: 20230123

**FILED AS OF DATE**: 20230123

**DATE AS OF CHANGE**: 20230123

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Autolus Therapeutics plc
- **CENTRAL INDEX KEY:** 0001730463
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** X0
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38547
- **FILM NUMBER:** 23545158

**BUSINESS ADDRESS:**
- **STREET 1:** THE MEDIAWORKS
- **STREET 2:** 191 WOOD LANE
- **CITY:** LONDON
- **STATE:** X0
- **ZIP:** W12 7FP
- **BUSINESS PHONE:** 44 20 3829 6230

**MAIL ADDRESS:**
- **STREET 1:** THE MEDIAWORKS
- **STREET 2:** 191 WOOD LANE
- **CITY:** LONDON
- **STATE:** X0
- **ZIP:** W12 7FP

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Autolus Therapeutics Ltd
- **DATE OF NAME CHANGE:** 20180205

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER**

**PURSUANT TO RULE 13a-16 OR 15d-16**

**UNDER THE SECURITIES EXCHANGE ACT OF 1934**

**For the Month of January 2023**

**Commission File Number: 001-38547**

**Autolus Therapeutics plc**

**(Translation of registrant's name into English)**

**The MediaWorks**

**191 Wood Lane**

**London W12 7FP**

**United Kingdom**

**(Address of principal executive office)**

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

x Form 20-F&nbsp;&nbsp;&nbsp;&nbsp;☐ Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

**INCORPORATION BY REFERENCE**

This Report on Form 6-K (the "Report"), excluding Exhibit 99.1 to this Report, shall be deemed to be incorporated by reference into the registration statements on Form F-3 (File No. 333-258556), Form F-3 (File No. 333-264304), Form F-3 (File No. 333-264650) and Form S-8 (File No. 333-226457) of Autolus Therapeutics plc (including any prospectuses forming a part of such registration statements) and to be a part thereof from the date on which this Report is furnished, to the extent not superseded by documents or reports subsequently filed or furnished.

------

**INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K**

On January 20, 2023, John H. Johnson, the chair of the Board of Directors (the "Board") of Autolus Therapeutics plc (the "Company"), notified the Company of his intention not to stand for re-election at the Company's 2023 Annual General Meeting of Shareholders. Mr. Johnson has indicated that this decision was not the result of any disagreement with the Company's management or Board.

On January 20, 2023, Dr. Jay T. Backstrom, a non-executive director of the Company, notified the Company of his intention to resign from the Board effective February 28, 2023. Dr. Backstrom has indicated that this decision was not the result of any disagreement with the Company's management or Board.

On January 20, 2023, the Company issued a press release announcing the aforementioned changes to the Board, which is furnished as Exhibit 99.1 to this Report

**EXHIBIT INDEX**

---

| | |
|:---|:---|
| **Exhibit<br>No.** | **Description** |
| <u>[99.1](pressreleasedatedjanuary.htm)</u> | Press release dated January 20, 2023 |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | | | |
|:---|:---|:---|:---|:---|
| | | **Autolus Therapeutics plc** | **Autolus Therapeutics plc** | **Autolus Therapeutics plc** |
| Date: | January 23, 2023 | By: | /s/ Christian Itin | /s/ Christian Itin |
|  |  |  | Name | Christian Itin, Ph.D. |
|  |  |  | Title: | Chief Executive Officer |

---

## Exhibit 99.1

![](pressreleasedatedjanuary001.jpg)

Autolus Therapeutics announces Board changes January 20, 2023 LONDON, Jan. 20, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, announces two changes to the company's Board of Directors. The company's non-executive Chairman, John H Johnson, who has held the role since September 2021, will not stand for re-election at Autolus' upcoming annual shareholder meeting. During his tenure as Chairman of Autolus he was appointed as Chief Executive Officer (CEO) of Reaction Biology and will focus his time on his operational role. Additionally, Dr Jay T Backstrom, who has served on Autolus' Board of Directors since August 2020, will step down from Autolus' Board of Directors at the end of February 2023. Dr Backstrom was recently appointed as CEO of Scholar Rock and will focus his time on his operational role in line with good governance recommendations for public company CEOs. "The Autolus Board and management team would like to thank John and Jay for their contributions and support during an important period in the company's transition to a late-stage biopharmaceutical company," said Dr. Christian Itin, Chief Executive Officer of Autolus. "During their tenure, Autolus' lead product candidate obe-cel met the primary end point in the pivotal FELIX trial and the company has started preparing for the regulatory approval process, as well as initiating preparations for commercialization." Searches to replace both Board members have been initiated. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts, and in some cases can be identified by terms such as "may," "will," "could," "expects," "plans," "anticipates," and "believes." These statements include, but are not limited to, statements regarding Autolus' planned governance changes. Any forward-looking statements are based on management's current views and assumptions and involve risks and uncertainties that could cause actual results, performance, or events to differ materially from those expressed or implied in such statements. For a discussion of the risks and uncertainties, and other important factors, any of which could cause Autolus' actual results to differ from those contained in the forward- looking statements, see the section titled "Risk Factors" in Autolus' Annual Report on Form 20-F filed with the Securities and Exchange Commission on March 10, 2022, as well as discussions of potential risks, uncertainties, and other important factors in Autolus' subsequent filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and Autolus undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise, except as required by law. Contact: Julia Wilson +44 (0) 7818 430877 j.wilson@autolus.com Susan A. Noonan S.A. Noonan Communications +1-917-513-5303 susan@sanoonan.com

------